Alessandro Grattoni is a Co-Founder of Continuity Biosciences. He is the Chair of the Department of Nanomedicine at The Methodist Hospital in Houston, TX. Dr. Grattoni's research focuses on developing and translating implantable nanofluidic technologies for drug delivery, molecular sieving, and cell transplantation. He works on creating silicon-based nanofluidic systems for controlled delivery of therapeutics, exploiting nanoscale physics to achieve sustained release of molecules over extended periods. Dr. Grattoni established his first commercial partnership with Mr. Whitehead in 2010. Subsequently, he has driven the maturation of multiple drug delivery technologies, and Mr. Whitehead's continued interest in that evolution culminated in the licensing of the associated IP from Methodist in June of 2024. Dr. Grattoni's team has secured more than $40 million in research funding from the NIH, DoD, JDRF, NASA, and private philanthropy, with additional grants currently pending. Dr. Grattoni will serve as Continuity’s Chief Scientific Advisor.